FDA accepts first generic tirzepatide application, from Sandoz

The FDA has accepted for review two applications from Sandoz for generic copies of tirzepatide, the active ingredient in Eli Lilly's Mounjaro and Zepbound. The June 29, 2026 acceptance covers all approved indications of both brand drugs, according to the company and trade reports ^[1][2][3][4].

An abbreviated new drug application, or ANDA, is the standard FDA pathway for generics. Acceptance means the agency checked that the paperwork was complete enough to review and placed it in the queue. It says nothing yet about whether the product is bioequivalent to Lilly's pens, whether manufacturing meets standards, or when a decision will come ^[1][2].

Sandoz says it developed both products in-house, drawing on its small-molecule chemistry and drug-delivery device work ^[1][2][4]. "Sandoz tirzepatide could be one of the first generic tirzepatide products available for patients in the U.S. on market formation," the company said in a statement ^[3].

How long review takes

The FDA's website says it expects to decide whether standard drugs are safe no more than 10 months after applications are received ^[3]. One report described roughly 10 months as the typical ANDA review window ^[1]. A separate analysis put approval for a product like tirzepatide at 12 to 24 months, because reviewers also have to evaluate the autoinjector device, not just the peptide ^[2].

Even a clean approval would not clear a generic to launch. Lilly's core composition-of-matter patent on tirzepatide runs to about January 2036 in the US ^[1][3][4]. Device and formulation patents could extend exclusivity into 2039 or later ^[1], with some running into the 2040s ^[2]. Method-of-use patents covering diabetes and obesity treatment run through the mid-2030s ^[2].

A generic maker has two routes around a live patent: win a Paragraph IV court challenge arguing the patent is invalid or not infringed, or negotiate a licensed early entry with the brand company. Neither is quick or guaranteed ^[1][2]. If Lilly sues in response to a Paragraph IV notice, it triggers a 30-month stay on FDA approval ^[2]. Sandoz has not disclosed which Lilly patents it is challenging, whether litigation has begun, or a target launch date beyond general marketing language ^[2].

Estimates of when a generic could actually reach pharmacies differ. One report pointed to a realistic 2036 to 2038 window ^[1]. Another wrote that FDA approval decisions are possible in 2027 to 2028, with a first launch window of 2028 to 2030 if Sandoz wins early patent challenges or settles with Lilly ^[2].

A second company has since filed. Amneal Pharmaceuticals and its partner Adalvo announced on July 8, 2026 that the FDA accepted two ANDAs covering a generic tirzepatide autoinjector ^[1]. A separate analysis, written around the same period, listed Amneal among the large generic makers that had not publicly announced a tirzepatide filing as of July 2026 ^[2].

Why it matters for patients

None of this changes today's options or prices. Zepbound single-dose vials through LillyDirect's self-pay program run $299 to $449 a month depending on dose ^[1]. A Medicare Part D program covering Zepbound KwikPen at a $50 monthly copay began July 1, 2026 ^[1]; under it, the net drug price is $245 a month, with CMS paying $195 ^[2]. That program ends December 31, 2027 ^[2].

Generic competition, when it arrives, could change how the drug is dispensed. If the FDA rates a generic tirzepatide autoinjector as therapeutically equivalent, pharmacies in 45 states could substitute it for the brand unless the prescriber writes "dispense as written"; five states have stricter rules ^[2]. Whether the device will get that rating has not been determined ^[2].

Compounded tirzepatide is a different system. Compounded products are made by a pharmacy for an individual patient and were never required to prove bioequivalence to the FDA ^[1]. That option narrowed after the FDA resolved the tirzepatide shortage in March 2025 and later moved to exclude tirzepatide from the 503B bulk substances list ^[1].

Analysts quoted in the coverage expect near-term price relief, if any, to come from branded discounting and coverage programs rather than generic entry ^[2].

What happens next

FDA decisions on the Sandoz applications could come around 2027 under the 10-month review clock ^[1], or in late 2027 to 2028 ^[2]. Sandoz's third-quarter 2026 earnings call, expected in October, may draw analyst questions on the timeline ^[2]. Any patent litigation would appear on federal court dockets and in the FDA Orange Book ^[2]. Teva, Amneal, Viatris and Aurobindo are among the largest US generic makers, and as of July 2026 none besides the filers had publicly announced tirzepatide ANDAs, according to one analysis ^[2].